1. Açık Erişim@BUU
  2. İndeksli Yayınlar
  3. Web of Science
Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/33935
Full metadata record
DC FieldValueLanguage
dc.contributor.authorButi, Maria-
dc.contributor.authorStepanova, Tatjana-
dc.contributor.authorCelen, Mustafa K.-
dc.contributor.authorFlisiak, Robert-
dc.contributor.authorRyder, Stephen D.-
dc.contributor.authorStreinu, Adrian Cercel-
dc.contributor.authorFlaherty, John F.-
dc.contributor.authorGaggar, Anu-
dc.contributor.authorSuri, Vithika-
dc.contributor.authorMo, Shuyuan-
dc.contributor.authorSubramanian, Mani-
dc.contributor.authorNurmukhametova, Elena-
dc.contributor.authorZoulim, Fabien-
dc.contributor.authorAndreone, Pietro-
dc.contributor.authorMarcellin, Patrick-
dc.date.accessioned2023-09-21T06:23:30Z-
dc.date.available2023-09-21T06:23:30Z-
dc.date.issued2017-10-
dc.identifier.citationButi, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.en_US
dc.identifier.issn0270-9139-
dc.identifier.issn1527-3350-
dc.identifier.urihttps://aasldpubs.onlinelibrary.wiley.com/loi/15273350-
dc.identifier.urihttp://hdl.handle.net/11452/33935-
dc.descriptionBu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipAmer Assoc Study Liver Disen_US
dc.description.sponsorshipGilead Sciencesen_US
dc.description.sponsorshipJohnson & Johnson Johnson & Johnson USA Janssen Biotech Incen_US
dc.description.sponsorshipAbbVieen_US
dc.description.sponsorshipRoche Holdingen_US
dc.description.sponsorshipAssemblypharmen_US
dc.description.sponsorshipContraviren_US
dc.description.sponsorshipArbutusen_US
dc.description.sponsorshipSanofien_US
dc.description.sponsorshipBristol-Myers Squibben_US
dc.description.sponsorshipMerck & Company Schering Plough Corporationen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.titleEfficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)en_US
dc.typeMeeting Abstracten_US
dc.identifier.wos000412089801057tr_TR
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı/Gastroenteroloji Bilim Dalı.tr_TR
dc.identifier.startpage488Atr_TR
dc.identifier.endpage488Atr_TR
dc.identifier.volume66tr_TR
dc.identifier.issueSupplement 1, Special Issueen_US
dc.relation.journalHepatologyen_US
dc.contributor.buuauthorGürel, Selim-
dc.contributor.researcheridHLH-8209-2023tr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.subject.wosGastroenterology & hepatologyen_US
dc.indexed.wosSSCIen_US
dc.indexed.wosCPCISen_US
dc.wos.quartileQ1en_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.